• CPD Modules
• General Practice
• Pain

Navigating codeine legislation: Safe practice and effective alternatives in acute pain

By Dr Bernard Kenny - 12th Jun 2026

---

Reference: June 2026 | Issue 6 | Vol 12 | Page 42

---

Start this Module to earn CPD Points today

Click the "Start Module" button below

Codeine remains the most commonly used opioid analgesic in Ireland, prescribed across general practice, emergency departments, and hospital services, and available in low-dose combination products through community pharmacies. Its place in routine clinical care has been reinforced by familiarity, perceived mildness, and decades of use.

For many patients and clinicians, codeine occupies an intermediate position between ‘simple analgesia’ and stronger prescription opioids. However, this apparent familiarity obscures a complex risk profile that warrants renewed scrutiny.

Unlike many analgesics, codeine is a pro-drug with considerable inter-individual variability in metabolism. Its analgesic effect depends on enzymatic conversion to morphine, and its adverse effects are influenced both by opioid toxicity and by the non-opioid components with which it is commonly combined. In clinical practice, codeine is frequently used for presentations that are painful but self-limiting, creating opportunities for repeated exposure that may outlast the underlying pathology.

Irish prescribing data show that analgesic and opioid prescribing increased substantially between 2014 and 2022, diverging from contemporaneous reductions observed in England.¹ This divergence has sharpened attention on opioid stewardship and has raised concerns regarding cumulative harm rather than isolated adverse events.

In parallel, the Health Products Regulatory Authority (HPRA) initiated a formal review of the appropriate method of sale for codeine-containing medicines in late 2022.² While the outcome of that review remains awaited, the process itself reflects growing awareness that routine exposure to codeine, particularly through combination products, carries public health implications.

For clinicians managing acute pain on a daily basis, the challenge is not whether codeine should ever be used; rather, it is how to determine when codeine is justified, when it is unlikely to add meaningful benefit, and how to support patients with safer, function-centred alternatives.

Codeine in context

Ireland’s approach to codeine exists within a diverse European regulatory landscape. Several EU Member States restrict all codeine-containing analgesics to prescription-only status, while Ireland and the UK have historically permitted supply of low-dose combination products under pharmacist supervision.³

Cross-country analyses consistently associate broader community access with higher rates of non-medical use, pharmacy shopping, and delayed help-seeking.⁴ In effect, repeated opioid exposure is displaced from standard prescribing pathways into a space where clinical oversight is less consistent.

These patterns are familiar in Irish primary care. Patients may present years into escalating use that developed gradually through self-management of pain rather than through a clearly defined initiating prescription. Community availability can obscure the transition from short-term use to dependence, particularly when patients perceive their behaviour as rational escalation of ‘safe’ analgesics rather than opioid exposure requiring review.

International experience provides further context. Australia rescheduled all codeine-containing products to prescription-only status in 2018. In the years following reclassification, multiple independent evaluations documented sustained reductions in population-level codeine consumption and codeine-related harms, including poison centre calls, emergency department presentations, and overdose deaths.^5-8 These findings were supported by wastewater-based analyses, which demonstrated a marked and sustained reduction in codeine metabolites without corresponding increases in indicators of higher-potency opioid use.⁹

Prospective cohort studies offer additional clinical reassurance. Among frequent codeine users, rescheduling was associated with reductions in daily consumption and prevalence of opioid use disorder, without deterioration in pain severity, anxiety, or depression scores.¹⁰ These data challenge the assumption that reduced availability necessarily leads to undertreated pain and suggest instead that function and mental health outcomes may be preserved.

Ireland’s healthcare system and prescribing culture differ from Australia’s, and regulatory change alone cannot be assumed to deliver identical outcomes. However, the Australian experience reinforces a principle directly relevant to Irish practice: Earlier recognition, structured review, and clinician engagement reduce harm more effectively than delayed response. Many observed benefits appear to arise not from reclassification alone, but from bringing repeated opioid exposure into settings where indication, duration, effectiveness, and emerging harms can be assessed.

Pharmacology

Codeine is a pro-drug whose analgesic effect depends on conversion to morphine via the CYP2D6 enzyme pathway. Genetic variability in CYP2D6 activity results in substantial inter-individual differences in both efficacy and toxicity. Poor metabolisers may derive little analgesic benefit and escalate doses in search of relief, while ultra-rapid metabolisers may experience pronounced opioid effects, including sedation and respiratory depression, at standard doses.^11,12 This variability challenges the assumption that codeine is a predictable or uniformly ‘mild’ opioid.

In routine clinical practice, significant harm often arises not from the opioid itself, but from the non-opioid components of combination products. Repeated or high-frequency use of paracetamol-containing combinations increases the risk of hepatotoxicity, while ibuprofen-containing products are associated with gastrointestinal bleeding, renal injury, and cardiovascular risk, particularly in older adults and during intercurrent illness.¹³ These toxicities may present before opioid dependence is recognised and should prompt careful reassessment of analgesic use.

Dependence is a recognised risk among regular users. Data from Ireland and the UK suggest that approximately one in six regular codeine users meets criteria for dependence when assessed using validated screening instruments.¹⁴ While this figure does not apply to short-term or occasional use, it is sufficiently high to justify routine enquiry regarding duration of use, dose escalation, and sourcing, particularly in patients presenting repeatedly with pain, gastrointestinal symptoms, or unexplained abnormalities in liver or renal indices.

Prescribing scenarios

In everyday clinical practice, codeine is rarely initiated for severe trauma or complex acute pain syndromes. Instead, it is most often introduced in presentations where recovery is expected and the natural history is favourable. These scenarios represent the greatest opportunity for safe prescribing, yet they are also the settings in which decisions are most vulnerable to contextual pressures.

Musculoskeletal injury: Acute ankle sprains, knee injuries, and shoulder strains commonly prompt requests for ‘stronger’ analgesia. In most cases, pain is inflammatory or mechanical in origin and responds well to paracetamol, NSAIDs, and early mobilisation. Adjunctive measures such as ice, compression, elevation, and graded return to activity relieve symptoms while supporting tissue recovery.

Codeine is often introduced several days into the course of illness, frequently driven by distress, sleep disruption, or frustration rather than objective functional impairment. This creates a critical decision point. Where pain meaningfully interferes with basic mobility or sleep despite optimised non-opioid therapy, a very short course of codeine may be considered. The risk arises when escalation becomes reflexive. In these situations, prescribing codeine can redirect attention away from rehabilitation and reinforce rest, passivity, and fear of movement. Early referral to physiotherapy, or at minimum explicit guidance on gradual return to function, improves outcomes and reduces reliance on escalating analgesia.

Lower back and dental pain: Acute non-specific low-back pain remains a frequent driver of opioid prescribing, despite strong evidence favouring non-pharmacological care.¹⁵ Most episodes resolve within weeks. Reassurance, advice to remain active, simple analgesia, and early mobilisation form the foundation of management. Heat therapy, manual therapies, and exercise-based approaches reduce fear-avoidance behaviours and support recovery. Opioids, including codeine, are unlikely to confer meaningful additional benefit in many cases and may prolong disability by encouraging inactivity.

Dental pain while awaiting definitive treatment represents another scenario in which codeine is commonly used despite limited benefit. NSAIDs are often superior due to their anti-inflammatory action, while codeine typically adds little additional analgesia and introduces avoidable risk.

Discharge prescribing: Codeine is frequently prescribed at discharge following minor procedures or short hospital admissions. ‘Just-in-case’ prescriptions issued without explicit stopping instructions normalise continued opioid use beyond the expected duration of acute pain. In the absence of clear guidance, patients may interpret possession of opioids as endorsement of ongoing use.

Discharge prescriptions should clearly specify indication, duration, and cessation once functional comfort is restored. Communication between hospital teams and general practitioners is essential to avoid duplication, unintended continuation, or escalation.

When to pause: Across these scenarios, a recurring theme is the psychological moment at which codeine feels like the appropriate next step. This moment often arises under time pressure, toward the end of a consultation, or when clinicians sense that reassurance alone may be perceived as insufficient. Pausing to ask whether codeine is likely to improve function, hasten recovery, or merely suppress symptoms temporarily can change prescribing decisions. In many cases, clearer explanation of expected recovery or earlier non-pharmacological intervention provides greater long-term benefit with substantially less risk.

Transitions of care

Transitions of care represent a well-recognised point of risk in medicines management, and codeine prescribing is no exception. In Irish practice, a significant proportion of new opioid exposure occurs at or around hospital discharge, often following short admissions, emergency department attendances, or minor procedures. While acute pain may justify short-term opioid use in selected cases, the way codeine is prescribed, communicated, and reviewed at discharge has a major influence on subsequent use.

Discharge prescriptions frequently include codeine on a precautionary basis, framed as an option should pain worsen after discharge. Where this occurs without clear indication, defined duration, or explicit stopping instructions, the intent of short-term use can be rapidly lost. Patients may interpret possession of opioid analgesia as endorsement of ongoing need, particularly if pain persists beyond the expected recovery window. In the absence of structured follow-up, such prescriptions can become de facto long-term treatment.

Communication between hospital teams and GPs is critical in mitigating this risk. Discharge summaries that list codeine among regular medications, rather than explicitly as timelimited analgesia, create ambiguity regarding responsibility for continuation or review. This ambiguity is compounded when patients are discharged with combination products, where cumulative exposure to paracetamol or ibuprofen is less visible across care settings.

From a general practice perspective, post-discharge consultations often occur several weeks after the initiating event, at a point where acute pain has evolved into persistent discomfort, deconditioning, or anxiety about recovery. At this stage, the decision to continue, stop, or escalate codeine is more complex, and opportunities for early deprescribing may already have been missed. Clear documentation at discharge regarding indication, intended duration, and stopping criteria supports safer review and reduces unintended continuation.

Hospital clinicians can support safer transitions by explicitly documenting when codeine is intended for short-term use only, specifying expected duration, and advising patients to stop once functional comfort is restored rather than completing a fixed course. Providing written advice on non-pharmacological pain management and setting expectations about recovery timelines further reduces reliance on opioid analgesia after discharge.

Similarly, GPs reviewing post-discharge analgesia should see medication reconciliation as a priority. Explicitly revisiting the original indication for codeine, assessing current function rather than pain score alone, and shifting emphasis toward mobilisation and rehabilitation can help prevent acute prescriptions from becoming entrenched. Where uncertainty exists, early follow-up rather than automatic continuation- is often the safer course.

Recognising transitions of care as a high-risk period for opioid exposure reinforces a central message of this module: Safe codeine prescribing does not depend solely on individual clinical decisions, but on how those decisions are communicated, documented, and revisited across care settings.

Patient communication

Communication is central to safe and effective pain management. Many patients equate stronger analgesia with better care and may interpret reluctance to prescribe opioids as minimisation of their pain. Clear, empathetic explanation is therefore essential.

Explaining that paracetamol and NSAIDs often provide comparable relief to codeine for common injuries helps recalibrate expectations. Framing recovery around function rather than pain scores encourages engagement with activity and rehabilitation. Patients should be reassured that some discomfort during healing is expected and does not indicate damage.

When codeine is prescribed, counselling should include advice on sedation, driving impairment, and alcohol avoidance. Patients should be warned explicitly about combining multiple paracetamol- or ibuprofen-containing products. Clear stopping rules are essential, along with guidance to seek reassessment rather than continuing analgesia independently if pain persists beyond the expected timeframe.

Non-pharmacological care

Non-pharmacological interventions are central, not ancillary, to the management of many acute pain conditions. Physiotherapy-guided exercise, graded return to activity, and manual therapies improve outcomes across musculoskeletal presentations. Early mobilisation supports tissue healing, prevents deconditioning, and reduces the risk of persistent pain.

Simple physical measures such as ice, heat, compression, and elevation remain effective. Behavioural and psychological factors also influence pain experience. Brief cognitive-behavioural approaches addressing fear-avoidance and catastrophising improve outcomes, while education regarding expected healing timelines often reduces perceived pain more effectively than pharmacological escalation.

Where access to physiotherapy or psychological therapies is limited, clinicians can still deliver meaningful benefit through structured self-management advice, written exercise programmes, and planned follow-up.

Codeine use disorder

Codeine use disorder often develops gradually and may remain unrecognised for years. Patients frequently describe progression from intermittent use to daily dosing, brand switching, and difficulty stopping as tolerance and withdrawal emerge. Assessment should be non-judgemental and focus on safety and function, including cumulative exposure to accompanying analgesics.

For patients with emerging problematic use, a structured taper combined with non-pharmacological pain management may be sufficient. Where dependence is established, opioid agonist therapy should be considered. Buprenorphine-naloxone is particularly suitable for many patients whose opioid exposure began with codeine, offering effective suppression of withdrawal and craving with a favourable safety profile.^16-18

Clinicians who are not trained to initiate opioid agonist therapy can still play a key role by identifying dependence early and facilitating referral. The website www.Drugs andalcohol.ie (the Health Research Board National Drugs Library) provides an up-to-date directory of HSE specialist addiction clinics and counselling supports across Ireland.

Conclusion

Codeine retains a limited role in acute pain management, but its risks require careful stewardship. Most acute pain can be managed effectively with non-opioid pharmacological measures and non-pharmacological strategies that prioritise function and recovery. Clear communication, thoughtful prescribing, and early identification of problematic use reduce harm and improve outcomes. For Irish clinicians making daily prescribing decisions, these principles provide a practical framework for safer care now, irrespective of future regulatory change.

Key points for practice

• Codeine offers limited or uncertain additional benefit over simple analgesics in many acute pain presentations.
• Early mobilisation, physiotherapy, and function-centred care improve recovery and reduce opioid reliance.
• The moment when codeine feels like the ‘next step’ is often the point at which practice can change.
• Clear counselling on duration, stopping rules, and duplication of paracetamol or NSAIDs is essential.
• Prolonged use of codeine combination products carries risks of dependence and cumulative non-opioid toxicity.
• drugsandalcohol.ie assists clinicians in identifying local HSE specialist addiction and counselling services.  

Start this Module to earn CPD Points today

Click the "Start Module" button below